NCT00858923Unknown1 期
Phase 1 Study of the HemoModulator System for the Treatment of Human Immunodeficiency Virus (HIV)
Energex Systems, Inc.2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2008年7月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 10
- 试验地点
- 2
- 主要终点
- Determine the therapy effectiveness on HIV-1 plasma viral load using PCR analysis Determine the therapy effects on CD4+, CD8+ cells and CD4/CD8 ratio
研究概览
简要总结
Tulane University Health Sciences Center/Louisiana Community AIDS Research
Center Program, New Orleans, LA is seeking patients for an HIV study. The
purpose of the study is to test the safety and effectiveness of an
experimental ultra-violet light device designed to reduce virus in your blood.
详细描述
You may be eligible if:
- You have HIV
- Your CD4 cell count is or greater than 400
- Your viral load is greater than 10,00 copies
- You do not yet qualify for standard antiviral therapy (HAART)
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of HIV-1 has been confirmed positive by ELISA and by Western Blot
- •Subject is not yet eligible for HAART
- •Subject's viral count at pre-baseline measured by RT-PCR is
- •10,000 copies /ml
- •Subject has a CD4+ count ≥ 400 cells/mm3
- •Subject's pre-screen EIA and RIBA test has proven negative for Hepatitis C virus
- •Female subjects with reproductive potential (and any male sexual partners) must agree to use a barrier device with spermicide (e.g., condoms, cervical cap, diaphragm) as the primary form of contraception, in addition to any other methods used, during treatment and until the end of the study to prevent pregnancy
- •Subject has taken no other anti-viral device or pharmacologic treatments in the 2 months prior to the first scheduled Hemo-Modulator study treatment
- •Subject agrees not to receive any other anti-viral device or anti-viral pharmacologic treatment (including herbal remedies) throughout the 21-week study period
- •Subject weighs at least 90 lbs (40.9 kg) at study initiation
- •Subject agrees to comply with study protocol requirements including all follow up visits through Day 60 of study duration
排除标准
- •Subjects with any other major illness (e.g., malignancy, renal failure, tuberculosis, porphyria, severe cardiac disease, severe neurological disease, or Hepatitis C) that would prevent completion of the study or bias efficacy assessments
- •Subjects with any other medical condition that the Investigator believes would make the patient unable to safely tolerate the extracorporeal blood volume required during the procedure [e.g., severe cardiovascular disease, history of congestive heart failure, or severe anemia (hemoglobin < 90 g/L)]
- •Subject with porphyria cutanea tarda (PCT), since PCT is associated with increased sensitivity to light and skin reactions such redness, pain, swelling and blistering after exposure to ultraviolet light
- •Subject has clinically abnormal hemotologic or chemistry laboratory values, defined as any parameter for these tests that exceeds Grade 1 (DAIDS Table for Grading the Severity of Adult Adverse Events, December 2004)
- •Subject has taken a steroid drug (other than Estrogen or Progesterone) within 7 days prior to study enrollment, or may require such medications during the course of study participation
- •Subject has taken a drug listed as photosensitizing in the Physician's Desk Reference (PDR) within 7 days prior to a Hemo-Modulator Treatment session
- •Subjects that habitually use excessive alcohol
- •Subjects that use illicit drugs or have an ongoing drug abuse problem
- •Subjects that have an acute systemic bacterial infection (septicemia)
- •Subjects that have been immunized for influenza within 7 days prior to study enrollment or is likely to require such immunization during the course of study participation
- •Subject is currently participating in another clinical investigation of a medical device, drug or biologic, or has participated in such a study within the 3 months prior to study enrollment
- •Subject is pregnant or plans on becoming pregnant within the next twelve months; or is lactating
- •Subject has a clotting deficiency
- •Subject is allergic to heparin
结局指标
主要结局
Determine the therapy effectiveness on HIV-1 plasma viral load using PCR analysis Determine the therapy effects on CD4+, CD8+ cells and CD4/CD8 ratio
时间窗: Once a week for 10 weeks
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
招募中
不适用
A Pilot Study Using the Aethlon Hemopurifier® in the Treatment of Chronic HCV Infection in Combination with Standard of Care Drug TherapyCTRI/2010/091/001114Aethlon Medical, Inc.8910 University Center Lane, Suite 660San Diego, CA 9212230
招募中
不适用
igeria PrEP Demonstration StudyHIV/AIDSPACTR201605001602542ational Agency for the Control of AIDS600
尚未招募
不适用
An mHealth Intervention to Improve HIV Prevention Service Engagement Among People Who Use DrugsHIV InfectionsNCT06068283University of California, San Diego40
已完成
1 期
Gene Therapy for Metachromatic Leukodystrophy (MLD)Metachromatic LeukodystrophyLysosomal Storage DiseaseNCT01560182Orchard Therapeutics20
进行中（未招募）
1 期
Gene therapy for WASWiskott-Aldrich syndrome (WAS) is a rare X-linked immunodeficiency caused by mutations in a single gene ,the Wiskott-Aldrich Syndrome Protein (WASP). WAS is characterised by micro-thrombocytopenia, recurrent infections,eczema and associated with a high incidence of auto-immunity and of lymphoid malignancies. Over 150 unique mutations in the WAS gene have been identified.Loss-of-function mutations in this gene have widespread consequences on hematopoietic lineages.MedDRA version: 19.1Level: PTClassification code 10047992Term: Wiskott-Aldrich syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2007-004308-11-GBGenethon